Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07276724 · ClinicalTrials.gov registry record · Phase 3
A Study to Investigate GB-0895 Adjunctive Therapy in Adults and Adolescents With Severe Uncontrolled Asthma (SOLAIRIA-1)
A Phase 3 study of Severe Asthma, sponsored by Generate Biomedicines.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 786
- Enrollment target
- 13
- Study locations
NCT07276724: Recruiting Phase 3 study of Severe Asthma, sponsored by Generate Biomedicines.
NCT07276724 is a Phase 3 study of Severe Asthma that is actively recruiting participants, run by Generate Biomedicines. The registered enrollment target is 786 participants, below the 3,768-participant average among 9 other Severe Asthma trials with a reported enrollment target (79% lower). The trial reports 13 study locations across 4 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07276724, a Phase 3 study of Severe Asthma, is actively recruiting participants, sponsored by Generate Biomedicines.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 786 participants
- Enrollment target
- 13
- Study locations
Study Summary
The objective of this study is to assess the potential for GB-0895 treatment to improve the health of adolescents and adults with severe asthma that is uncontrolled by inhaled corticosteroids (ICS) and conventional asthma controllers. The study details include: Study treatment: randomized to receive either GB-0895 or placebo administered every 6 months over 52 weeks. Visit frequency: every 1-2 months after the first month.
Primary Outcome
The annual exacerbation rate is based on clinically significant (CS) exacerbations reported by the investigator in the electronic case (eCRF) over 52 weeks for subjects on GB-0895 as compared to placebo.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG GB-0895
Study Locations (13)
Florida
- Research Site 12 - Doral
- Research Site 03 - Hialeah
- Research Site 04 - Miami
- Research Site 01 - Miami Lakes
- Research Site 08 - North Miami
- Research Site 10 - Palm Springs
- Research Site 02 - Tampa
Texas
- Research Site 07 - Dallas
- Research Site 11 - Houston
- Research Site 09 - Houston
- Research Site 05 - Lewisville
California
- Research Site 13 - West Hills
Michigan
- Research Site 06 - Flint
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 786 participants |
| Start Date | 2025-12-03 |
| Est. Completion | 2028-12 |
| Phase | Phase 3 |
What NCT07276724 shows while recruiting
NCT07276724 is an interventional study that assigns participants to a tested intervention. The registered 786 participants enrollment target is mid-sized for trials with a published cap, below the 3,768-participant average among 9 other Severe Asthma trials with a reported enrollment target (79% lower).
The record links to 1 condition, with Severe Asthma appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT07276724 lists 13 locations in 4 states (Florida, Texas, California).
Frequently Asked Questions
What is clinical trial NCT07276724 about?
NCT07276724 is a clinical study titled "A Study to Investigate GB-0895 Adjunctive Therapy in Adults and Adolescents With Severe Uncontrolled Asthma (SOLAIRIA-1)". The objective of this study is to assess the potential for GB-0895 treatment to improve the health of adolescents and adults with severe asthma that is uncontrolled by inhaled corticosteroids (ICS) and conventional asthma controllers. The study details include: Study treatment: randomized to recei...
What is the current status of trial NCT07276724?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 786 participants. The study started on 2025-12-03. Estimated completion is 2028-12.
What conditions does trial NCT07276724 study?
This clinical trial studies the following conditions: Severe Asthma.
What interventions are being tested in trial NCT07276724?
The interventions under investigation include: Placebo (DRUG), GB-0895 (DRUG).
Who is sponsoring clinical trial NCT07276724?
This trial is sponsored by Generate Biomedicines, which has 5 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07276724 being conducted?
This trial has 13 study locations across California, Florida, Michigan, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Severe Asthma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT07276724's enrollment target sits among peer trials
786 2nd of 9 higher than 7 of 9 other Severe Asthma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Severe Asthma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study to Investigate GB-0895 Adjunctive Therapy in Adults and Adolescents With Severe Uncontrolled Asthma (SOLAIRIA-2)
RECRUITING · Phase 3
-
Open-label Study to Assess Reduction of Background Asthma Medication While Sustaining Asthma Control and Clinical Remission With Tezepelumab in Patients 12-80yrs With Severe Asthma.
ACTIVE NOT RECRUITING · Phase 3
-
Downstream Effects of Airway Mucus Plugs on 129Xenon MRI in Severe Asthma
RECRUITING
-
A Long-Term Safety and Efficacy Study of Verekitug (UPB-101) in Adult Participants With Severe Asthma (VALOUR)
RECRUITING · Phase 2
-
Phenotyping Asthma for Bronchial Thermoplasty
RECRUITING
-
Evaluation of Ventilation Defects Downstream of Mucus Plugs in Patients With Severe Asthma
RECRUITING
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06488781 · 787 participants · Phase 2
Antibiotic Prophylaxis to Prevent Obesity-Related Induction Complications in Nulliparae at Term 2.0
- NCT06876649 · 787 participants · Phase 4
A Master Protocol to Evaluate the Long-Term Safety of (LY3527727) Pirtobrutinib
- NCT06498128 · 785 participants
Registry to Collect Information on Pregnancy, Neonatal, and Infant Outcomes in Pregnant Women Exposed to QUVIVIQ®
- NCT06118723 · 784 participants
The SUPRAMAX Study: Supramaximal Resection Versus Maximal Resection for High-Grade Glioma Patients (ENCRAM 2201)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI